Safety and antigenicity of influenza A/Hong Kong/68-ts-1 (E) (H3N2)
- PMID: 810557
- DOI: 10.1016/s0022-3476(75)80123-5
Safety and antigenicity of influenza A/Hong Kong/68-ts-1 (E) (H3N2)
Abstract
Influenza A/Hong Kong/68-ts-1 [E] (H3N2) vaccine was administered intranasally to 18 seronegative children 14 to 32 months of age. Fourteen children, 78%, shed influenza A/Hong Kong virus for a mean of eight days following vaccination. Sixteen children, 89%, experienced a fourfold or greater rise in hemagglutination-inhibition antibody. Some children appeared to experience a febrile reaction to the vaccine although interpretation of this data was complicated by intercurrent illness. These findings demonstrate that influenza A ts-1 [E] replicates more readily in the young seronegative child than in the HAI negative adult. In addition, the temperature-sensitive marker of the vaccine was not genetically stable in four of the vaccinated children. Careful evaluation of any future live respiratory viral vaccines needs to be undertaken in the young seronegative child before the vaccine's safety is fully established.
Similar articles
-
Temperature-sensitive mutants of influenza A virus: response of children to the influenza A/Hong Kong/68-ts-1(E) (H3N2) and influenza A/Udorn/72-ts-1(E) (H3N2) candidate vaccine viruses and significance of immunity to neuraminidase antigen.Pediatr Res. 1976 Apr;10(4):238-42. doi: 10.1203/00006450-197604000-00008. Pediatr Res. 1976. PMID: 1272630
-
Live, attenuated influenza A/England/42/72 (H3N2) virus vaccine: a field trial.J Infect Dis. 1976 Jun;133(6):613-20. doi: 10.1093/infdis/133.6.613. J Infect Dis. 1976. PMID: 778302 Clinical Trial.
-
Live attenuated influenza vaccines in young seronegative children.Dev Biol Stand. 1977 Jun 1-3;39:99-103. Dev Biol Stand. 1977. PMID: 604140
-
Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine.J Infect Dis. 1992 Apr;165(4):727-32. doi: 10.1093/infdis/165.4.727. J Infect Dis. 1992. PMID: 1552202 Clinical Trial.
-
Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.Drugs R D. 2003;4(5):312-9. doi: 10.2165/00126839-200304050-00007. Drugs R D. 2003. PMID: 12952502 Review.
Cited by
-
Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine.J Virol. 1995 Oct;69(10):5969-77. doi: 10.1128/JVI.69.10.5969-5977.1995. J Virol. 1995. PMID: 7666501 Free PMC article.
-
Humoral and cellular immune responses of seronegative children vaccinated with a cold-adapted influenza A/HK/123/77 (H1N1) recombinant virus.Infect Immun. 1980 Mar;27(3):862-6. doi: 10.1128/iai.27.3.862-866.1980. Infect Immun. 1980. PMID: 6155338 Free PMC article. Clinical Trial.
-
Use of the enzyme-linked immunosorbent assay to detect serum antibody responses of volunteers who received attenuated influenza A virus vaccines.Infect Immun. 1980 Aug;29(2):342-7. doi: 10.1128/iai.29.2.342-347.1980. Infect Immun. 1980. PMID: 7011972 Free PMC article.
-
Temperature-sensitive mutants of influenza A virus: evaluation of A/Victoria/3/75-ts-1[E] recombinant viruses in volunteers.Infect Immun. 1978 Jun;20(3):671-7. doi: 10.1128/iai.20.3.671-677.1978. Infect Immun. 1978. PMID: 669819 Free PMC article.
-
Live Victoria/75-ts-1[E] influenza A virus vaccines in adult volunteers: role of hemagglutinin immunity in protection against illness and infection caused by influenza A virus.Infect Immun. 1979 Oct;26(1):274-9. doi: 10.1128/iai.26.1.274-279.1979. Infect Immun. 1979. PMID: 500204 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical